AIM ImmunoTech (AIM) Scheduled to Post Earnings on Tuesday

AIM ImmunoTech (NYSE:AIMGet Free Report) will announce its earnings results on Tuesday, April 2nd.

AIM ImmunoTech Trading Up 6.3 %

AIM opened at $0.47 on Monday. The stock has a market cap of $23.00 million, a price-to-earnings ratio of -1.10 and a beta of -0.13. AIM ImmunoTech has a 1 year low of $0.32 and a 1 year high of $0.75. The stock has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.45.

Insider Activity at AIM ImmunoTech

In other news, Director Stewart Appelrouth acquired 90,910 shares of AIM ImmunoTech stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $0.33 per share, with a total value of $30,000.30. Following the completion of the transaction, the director now owns 239,765 shares in the company, valued at $79,122.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Stewart Appelrouth bought 90,910 shares of the business’s stock in a transaction on Friday, March 15th. The shares were bought at an average cost of $0.33 per share, for a total transaction of $30,000.30. Following the completion of the acquisition, the director now directly owns 239,765 shares in the company, valued at $79,122.45. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Thomas K. Equels bought 75,758 shares of the business’s stock in a transaction on Friday, March 15th. The shares were bought at an average price of $0.33 per share, for a total transaction of $25,000.14. Following the completion of the acquisition, the chief executive officer now owns 716,455 shares of the company’s stock, valued at $236,430.15. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 243,009 shares of company stock valued at $82,501. Insiders own 0.02% of the company’s stock.

Hedge Funds Weigh In On AIM ImmunoTech

Institutional investors have recently bought and sold shares of the stock. DRW Securities LLC bought a new position in AIM ImmunoTech during the second quarter valued at about $25,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of AIM ImmunoTech in the first quarter worth about $49,000. Virtu Financial LLC increased its stake in shares of AIM ImmunoTech by 34.9% in the first quarter. Virtu Financial LLC now owns 50,805 shares of the company’s stock worth $54,000 after purchasing an additional 13,148 shares during the period. Renaissance Technologies LLC increased its stake in shares of AIM ImmunoTech by 23.2% in the first quarter. Renaissance Technologies LLC now owns 168,708 shares of the company’s stock worth $73,000 after purchasing an additional 31,800 shares during the period. Finally, State Street Corp increased its stake in shares of AIM ImmunoTech by 7.9% in the first quarter. State Street Corp now owns 173,103 shares of the company’s stock worth $183,000 after purchasing an additional 12,690 shares during the period. 12.02% of the stock is currently owned by institutional investors.

About AIM ImmunoTech

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

Featured Articles

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.